ADAMTSL4 and nasopharyngeal carcinoma: Commercial ELISA kit was used for these two type of patients and it has identified that the serum ADAMTSL4 levels were much lower in metastasis NPC patients than those in non-metastasis NPC patients (P = 0.045), whereas the serum TXN levels were similar for the NPC patients with and without metastasis (P = 0.142) (Table 4).